Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration

The Journal of Antimicrobial Chemotherapy
Valentin FuhrmannFlorian Thalhammer

Abstract

Moxifloxacin is an 8-methoxy quinolone with a broad range of activity against clinically important pathogens. Therefore it is frequently administered in severe respiratory tract infections. Continuous venovenous haemodiafiltration (CVVHDF) is an important extracorporeal renal replacement therapy for intensive care patients suffering from sepsis and multiple organ failure. The aim of this study was to investigate the pharmacokinetics of intravenous moxifloxacin in anuric critically ill patients undergoing CVVHDF. Pharmacokinetic analysis was performed in nine intensive care patients with acute renal failure and suspected or proven infection sensitive to moxifloxacin, who received moxifloxacin 400 mg intravenously once daily. The concentration of moxifloxacin in serum and ultradiafiltrate was determined by HPLC. Peak and trough serum concentrations were 3.76 +/- 2.02 mg/L and 0.24 +/- 0.14 mg/L, respectively, at the arterial port after the first dose. The mean elimination half-life was 9.87 +/- 3.26 h, the volume of distribution 270 +/- 133 L and the calculated AUC0-24 18.41 +/- 8.46 mg.h/L. Total clearance was 19.09 +/- 8.22 L/h and the clearance of haemodiafiltration 1.63 +/- 0.33 L/h. The pharmacokinetics of moxifloxacin in cr...Continue Reading

References

Nov 1, 1995·The Journal of Antimicrobial Chemotherapy·S Cotterill
Nov 1, 1996·Chemotherapy·A DalhoffR Endermann
Aug 1, 1997·Antimicrobial Agents and Chemotherapy·R J Fass
Aug 26, 1998·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·M MannsB P Teehan
Jun 25, 1999·The Journal of Antimicrobial Chemotherapy·P D Lister, C C Sanders
Jun 26, 1999·The Journal of Antimicrobial Chemotherapy·H Stass, D Kubitza
May 8, 2000·The Journal of Antimicrobial Chemotherapy·E PestovaL R Peterson
Feb 7, 2001·The Journal of Antimicrobial Chemotherapy·F TraunmüllerF Thalhammer
Apr 25, 2001·Journal of Chromatography. B, Biomedical Sciences and Applications·B B BaM C Saux
Mar 5, 2002·British Journal of Clinical Pharmacology·H StassH Delesen
Oct 10, 2003·Clinical Pharmacology and Therapeutics·Nicolas SimonBernard Bruguerolle

❮ Previous
Next ❯

Citations

Dec 20, 2008·Current Infectious Disease Reports·Guillaume Dufour, Philippe Montravers
Sep 16, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Robin L TrotmanWilliam L Salzer
Jul 11, 2009·The Journal of Antimicrobial Chemotherapy·Renu SinghVincent H Tam
Mar 12, 2011·The Journal of Antimicrobial Chemotherapy·Judith M LeitnerFlorian Thalhammer
Mar 12, 2011·The Journal of Antimicrobial Chemotherapy·Pratik BhagundeVincent H Tam
Jun 3, 2009·Critical Care Medicine·Gordon ChoiJeffrey Lipman
Mar 25, 2008·Therapeutics and Clinical Risk Management·David Rp Guay
Nov 5, 2013·Journal of Women's Health·Elisa Chilet-RosellMa Angeles Pardo
Oct 23, 2013·Antimicrobial Agents and Chemotherapy·Thomas HorvatitsPeter Schenk
Jun 15, 2007·Current Medical Research and Opinion·Paul B Iannini
Apr 17, 2009·Néphrologie & thérapeutique·Vincent BourquinPierre-Yves Martin
Dec 20, 2007·The Journal of Pharmacy and Pharmacology·Salwa AhmedWalter Jäger
Dec 15, 2012·Acta Anaesthesiologica Scandinavica·G A RothC G Krenn
Mar 29, 2016·Expert Review of Clinical Pharmacology·Nynke Gl JagerJason A Roberts
Sep 4, 2009·Clinical Pharmacology and Therapeutics·G M Susla
Apr 3, 2012·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Fumi SuzukiHiroyasu Ogata
Jun 29, 2005·The Journal of Antimicrobial Chemotherapy·K P IttnerK Taeger
Aug 21, 2007·Clinical Journal of the American Society of Nephrology : CJASN·David CzockJan T Kielstein
Aug 18, 2009·Expert Review of Anti-infective Therapy·Olaf Burkhardt, Tobias Welte
Jul 23, 2015·AACN Advanced Critical Care·Gregory M Susla
May 22, 2019·Antimicrobial Agents and Chemotherapy·Valentina PistolesiEnrico Fiaccadori

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.